Swedish Universities Lead Breakthrough in Understanding Antibiotic Effects on Gut Health
The gut microbiome, often called the body's 'second brain,' plays a crucial role in digestion, immune function, and even mental health. Comprising trillions of microorganisms, primarily bacteria, it helps break down food, produce vitamins, and protect against pathogens. Disruptions to this delicate ecosystem can lead to issues like obesity, type 2 diabetes, and inflammatory bowel disease (IBD). A groundbreaking study from Swedish researchers has now shown that common antibiotics can cause persistent changes to the gut microbiome lasting up to eight years, even from a single course of treatment.
Published on March 11, 2026, in Nature Medicine, the research highlights how specific antibiotics reshape microbial diversity and species composition long-term. Led by teams at Uppsala University and Lund University, this work underscores Europe's strength in population-based health research, leveraging Sweden's comprehensive national registers and biobanks.
Background: Why Antibiotic Impacts Matter
Antibiotics are life-saving drugs targeting bacterial infections, but they are not selective—they kill beneficial gut bacteria too. Short-term disruptions are well-known, with diversity dropping immediately after use and partially recovering within months. However, long-term effects have been harder to quantify due to challenges in tracking individuals over years. Sweden's low antibiotic consumption—one of Europe's lowest at around 12 defined daily doses per 1,000 inhabitants daily—provides an ideal setting, as microbiomes are less 'pre-conditioned' by frequent exposure compared to higher-use countries like the US or southern Europe.
Prior studies suggested links between antibiotics and chronic conditions, but lacked precision on duration or specific drugs. This new investigation fills that gap, using advanced metagenomic sequencing to profile over 1,340 bacterial species.
The Groundbreaking Methodology
The study analyzed fecal metagenomes from 14,979 adults across three Swedish cohorts: the Swedish Cardiopulmonary BioImage Study (SCAPIS, n=8,488), Swedish Infrastructure for Medical Population-Based Life-Course Epidemiology Research (SIMPLER, n=4,784), and Malmö Offspring Study (MOS, n=1,707). Participants underwent shotgun metagenomic sequencing for detailed microbiome mapping.
Researchers linked this to the Swedish Prescribed Drug Register (NPDR), tracking oral antibiotic prescriptions (ATC code J01) up to eight years prior. Exposure was categorized as <1 year, 1–4 years, or 4–8 years before sampling. Models adjusted for confounders like age, sex, BMI, smoking, comorbidities, and other medications (e.g., proton pump inhibitors, statins).
Outcomes included alpha-diversity metrics (Shannon index, species richness, inverse Simpson) and relative abundances of prevalent species. Meta-analyses combined cohort results, with sensitivity tests confirming robustness.
Specific Antibiotics and Their Long-Term Toll
Not all antibiotics are equal in their impact. Clindamycin, fluoroquinolones (e.g., ciprofloxacin for urinary tract infections), and flucloxacillin (for skin infections) showed the strongest associations. Use 4–8 years earlier altered abundances of 10–15% of studied species—around 130–200 species each.
| Antibiotic | Species Richness Reduction (<1 year) | Persistent Species Affected (4–8 years) |
|---|---|---|
| Clindamycin | ~47 species | 196 (single course) |
| Fluoroquinolones | ~20 species | 80 |
| Flucloxacillin | ~21 species | 148 |
| Penicillin V | Minimal | Few |
| Nitrofurantoin | Minimal | Few |
Effects were dose-dependent initially but persisted even from one course. Broad-spectrum drugs like clindamycin reached high colon levels, explaining greater disruption. Surprisingly, narrow-spectrum flucloxacillin had outsized effects, possibly due to bile excretion concentrating it in the gut. For full details, see the open-access study.
Recovery Patterns: Slow and Incomplete
Functional models showed rapid partial recovery in the first two years post-exposure, proportional to initial damage. Thereafter, changes stabilized, with incomplete restoration even after eight years. Species like Enterocloster bolteae and Ruminococcus gnavus (depleted by these antibiotics) link to higher BMI and diabetes risk, while others like Alistipes communis correlate with better cardiometabolic health.
Depletions mirrored IBD-associated species, suggesting heightened infection vulnerability long-term.
Health Risks Tied to Microbiome Shifts
Lower diversity associates with obesity, type 2 diabetes, cardiovascular disease, and colorectal cancer. This study confirms antibiotics promote pro-inflammatory species while depleting protective ones. In Sweden, where stewardship limits use, effects are pronounced—implying greater risks elsewhere.
Uppsala's press release notes: “Even a single course leaves traces,” per first author Gabriel Baldanzi. Lund's Marju Orho-Melander adds context to prior disease links. Implications extend to antibiotic resistance, as disrupted microbiomes foster pathogens like Clostridioides difficile.
Sweden's Antibiotic Stewardship: A European Model
Sweden exemplifies prudent prescribing, with national guidelines and monitoring via STRAMA (Swedish Strategic Programme Against Antibiotic Resistance). This study, from Uppsala and Lund, reinforces such efforts. Read more in Uppsala's press release and Lund's update.
Expert Insights from Leading Researchers
Principal investigator Tove Fall (Uppsala): “The strong link between narrow-spectrum flucloxacillin and the gut microbiome was unexpected... may help inform future recommendations.” Anna Larsson (Lund PhD student/GP): “Choose antibiotics with least gut impact when possible.”
International experts like Jotham Suez praise the scale, noting diversity-health links need nuance—specific species matter more.
Broader Implications for European Higher Education and Research
This collaboration showcases Sweden's infrastructure: national registers, biobanks, Science for Life Laboratory. It positions Uppsala and Lund as microbiome leaders, attracting funding (Swedish Research Council, ERC). Europe-wide, it informs EU antibiotic action plans, emphasizing precision prescribing.
Future Outlook: Interventions and Ongoing Studies
Follow-up samples from half participants will track recovery. Potential for probiotics or fecal transplants? Current evidence limited, per 2024 reviews. Diet (high-fiber) aids resilience. Research jobs in microbiome at Swedish universities proliferate, fostering innovation.
Actionable Takeaways for Clinicians and Patients
- Prioritize narrow-spectrum when possible (e.g., penicillin V over clindamycin).
- Reserve fluoroquinolones/flucloxacillin for necessity.
- Support recovery: probiotics (limited evidence), prebiotics, diverse diet.
- Discuss history with doctors for microbiome-informed care.
This study revolutionizes our view of antibiotics' legacy, urging balanced use while celebrating Swedish research prowess.
Photo by Veronica H on Unsplash